Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks.

Hatfield KJ, Evensen L, Reikvam H, Lorens JB, Bruserud Ø.

Eur J Haematol. 2012 Dec;89(6):478-90. doi: 10.1111/ejh.12016. Epub 2012 Oct 26.

PMID:
23046151
4.

Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts.

Bruserud Ø, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT.

Haematologica. 2004 Apr;89(4):391-402.

6.

Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.

Hatfield K, Øyan AM, Ersvaer E, Kalland KH, Lassalle P, Gjertsen BT, Bruserud Ø.

Br J Haematol. 2009 Jan;144(1):53-68. doi: 10.1111/j.1365-2141.2008.07411.x. Epub 2008 Oct 30.

PMID:
19016730
7.
8.

Sertoli cells enhance formation of capillary-like structures in vitro.

Golat BT, Cameron DF.

Cell Transplant. 2008;17(10-11):1135-44.

PMID:
19181208
9.

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.

Bruserud Ø, Ryningen A, Olsnes AM, Stordrange L, Øyan AM, Kalland KH, Gjertsen BT.

Haematologica. 2007 Mar;92(3):332-41.

10.

T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005.

Ersvaer E, Hampson P, Hatfield K, Ulvestad E, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø.

Cancer Immunol Immunother. 2007 Jun;56(6):913-25. Epub 2006 Nov 8.

PMID:
17115221
13.

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.

Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O.

Eur J Haematol. 2010 Mar;84(3):239-51. doi: 10.1111/j.1600-0609.2009.01382.x. Epub 2009 Nov 17.

PMID:
19922462
14.

[Angiogenesis in patients with hematologic malignancies].

Mesters RM, Padró T, Steins M, Bieker R, Retzlaff S, Kessler T, Kienast J, Berdel WE.

Onkologie. 2001 Sep;24 Suppl 5:75-80. Review. German.

PMID:
11600818
15.

T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC).

Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud Ø.

Cancer Immunol Immunother. 2006 Jul;55(7):830-40. Epub 2005 Nov 3.

PMID:
16267679
17.

Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells.

Hatfield KJ, Bedringsaas SL, Ryningen A, Gjertsen BT, Bruserud O.

Eur Cytokine Netw. 2010 Sep;21(3):154-64. doi: 10.1684/ecn.2010.0204. Epub 2010 Aug 20.

18.

Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts.

Bruserud Ø, Huang TS, Glenjen N, Gjertsen BT, Foss B.

Haematologica. 2002 Jun;87(6):584-95.

19.

The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells.

Smits EL, Cools N, Lion E, Van Camp K, Ponsaerts P, Berneman ZN, Van Tendeloo VF.

Cancer Immunol Immunother. 2010 Jan;59(1):35-46. doi: 10.1007/s00262-009-0721-8. Epub 2009 May 16.

PMID:
19449004
20.

Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells.

Köhler T, Plettig R, Wetzstein W, Schmitz M, Ritter M, Mohr B, Schaekel U, Ehninger G, Bornhäuser M.

Stem Cells. 2000;18(2):139-47.

Supplemental Content

Support Center